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Vitamin D deficiency following malabsorptive bariatric surgery can lead to osteomalacia. We report a
patient with severe vitamin D deficiency following malabsorptive bariatric surgery successfully
treated with calcifediol but not cholecalciferol. A 40-year-old woman, submitted to biliopancreatic
diversion 20 years before and chronically treated with 50,000 IU cholecalciferol weekly, was admitted
to our Endocrine Unit because of severe lower back pain, muscle weakness, and generalized muscular
hypotrophy, associated with hypocalcemia and elevated PTH levels. Initial evaluation revealed low
serum albumin, low albumin-corrected serum calcium (7.36 mg/dL), high serum PTH (240 pg/mL),
bone-specific alkaline phosphatase (125 mg/L) and 1,25-dihydroxyvitamin D (112 pg/mL) concen-
trations, undetectable serum 25-hydroxyvitamin D (,7 ng/mL), and evidence of reduced liver
function. Bone mineral density was markedly low. Normocalcemia was initially restored with in-
travenous albumin and calcium gluconate. Treatment with calcitriol (0.5 mg three times daily) and
oral calcium carbonate (1000 mg daily) was simultaneously started and cholecalciferol was replaced
with calcifediol [125 mg (5000 IU) daily)]. During follow-up the calcifediol dose was progressively
tapered to 25 mg (1000 IU) daily and the calcitriol dose was progressively reduced and finally
withdrawn. Serum albumin and other biochemical parameters normalized, bone mineral density
significantly increased, and the patient’s clinical conditions progressively improved, with a sub-
stantial recovery of autonomy. Serum vitamin D binding protein at the last observation was in the
normal range. Our data suggest that calcifediol might be more efficacious than cholecalciferol for
prevention and treatment of vitamin D deficiency in patients treated by malabsorptive bariatric
surgery.
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Severe obesity is frequently associated with vitamin D deficiency [1]. The prevalence of
vitamin D deficiency in patients who undergo bariatric surgery is dependent on the type of
procedure performed.Malabsorptive interventions involve bypassing a large part of the small
intestine, so that fat absorption is confined to the more distal sections. Such interventions,
despite being associated with a greater weight loss compared with nonmalabsorptive pro-
cedures, are even associated with a higher frequency of postoperative vitamin D deficiency,
osteomalacia, aswell as a high risk of hypocalcemia and fragility fractures [2]. Currently there
is no clear consensus on the modality and the doses of vitamin D supplementation in patients
previously submitted to bariatric surgery.
Abbreviations: 25(OH)D, 25-hydroxyvitaminD; BMD, bonemineral density; BSAP, bone-specific alkaline phosphatase; DBP, vitamin
D binding protein.
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1. Case Presentation
A 40-year-old woman presented to the emergency department (February 2016) of a local
primary care hospital for a subocclusive episode and admitted to a short-stay observation
ward. Current treatment consisted of slow-release tramadol (100mgdaily) and cholecalciferol
(50,000 IU weekly). The subocclusive episode resolved spontaneously. Routine blood tests
revealed severe hypocalcemia (6.6 mg/dL; normal range, 8.6 to 10.2) and markedly elevated
PTH (234 ng/mL; normal range, 8 to 40) levels. The patient was transferred to our unit for
further evaluation.
Themedical history revealed that she had undergone biliopancreatic diversion for stage III
obesity 20 years earlier. Since then, she was submitted to two major surgical procedures for
bowel obstruction due to adherences (at 26 years of age) and for small bowel perforation (at
36 years of age). Thereafter she developed several minor bowel subocclusive episodes that
were treated medically.
Five years before the admission to our hospital, the patient discontinued follow-up but
continued to take regularly the weekly dose of cholecalciferol (50,000 IU). Careful reevalu-
ation of biochemical data revealed that serum levels of 25-hydroxyvitamin D [25(OH)D] were
low (,10 ng/mL) or undetectable during the 5 years prior to the admission, associated with
increased levels of PTH and alkaline phosphatase.
Fourteen months before she developed an atraumatic fracture of the right hip, which was
treated surgically, and 6months before a fracture of the first lumbar vertebrawas incidentally
discovered during evaluation for sudden-onset severe lower back pain with progressive
immobilization. Her family history was unremarkable.
Nutritional status was inadequate. Physical examination revealed pigeon chest, arterial
hypotension, and generalized muscular hypotrophy due to immobilization. Chvostek and
Trousseau signs were negative. Other vital signs were normal. Herweight was 65 kg and height
1.63m (bodymass index, 24.5 kg/m2). Intestinal functionwas characterized bymild steatorrhea,
which persisted when the vitamin D therapeutic regimen was modified (see later). Upon
questioning, both the patient and her relatives assured full adherence to cholecalciferol therapy.
Laboratory examination revealed macrocytic-normocromic anemia: hemoglobin 8.8 g/dL
(normal range, 11.5 to 15.5), cell volume 103.1 fL (normal range, 80 to 96), cell hemoglobin
content 31.8 pg (normal range, 27 to 32).
Other significant laboratory values included: low serum total calcium (6.4 mg/dL),
phosphate (1.1 mg/dL; normal range, 2.7 to 4.5), albumin (2.8 g/dL; normal range, 3.6 to
5.2), and albumin-corrected serum total calcium (7.36 mg/dL) concentrations; normal mag-
nesium (2.12mg/dL; normal range, 1.6 to 2.6), undetectable levels of 25(OH)D; and high levels
of bone-specific alkaline phosphatase (BSAP; 125 mg/L; normal range, 2 to 28), 1,25-dihy-
droxyvitamin D (112 pg/mL; normal range, 20 to 67), and PTH (240 pg/mL). Liver function
tests were consistent with a reduced synthesis function, as revealed by low serum levels of
albumin, cholinesterase (2435 IU/L; normal range, 4200 to 11,200), and transferrin (1.8 g/L;
normal range, 2 to 3.6). Othermeasurements related to the nutritional status, namely retinol-
binding protein (undetectable), prealbumin (13 mg/dL; normal range, 20 to 40), were con-
sistent with the severely deficient nutritional status despite an average daily caloric intake of
1800 kcal, but a low daily calcium intake (about 200 mg/d).
Chest x-rays showed a mild bilateral pleural effusion. Numerous areas of pathological
uptake at the ribs, stern, hips, and cranium, suggestive for metabolic osteopathy, were de-
tected at 99mTc-oxidronate whole-body scan (Fig. 1). Dual x-ray absorptiometry revealed
a severe reduction in bone mineral density (BMD), both at the total hip (0.417 g/cm2, z score
24.3) and lumbar spine (0.491 g/cm2, z score 25.3). X-rays of long bones and hips revealed
diffuse and marked osteopenia.
All of these features were consistent with the consequence of chronic hypocalcemia and
osteomalacia due to severe vitamin D deficiency.
The patient was initially treated with intravenous albumin and calcium gluconate and
started with calcitriol (0.5 mg three times daily) and oral calcium carbonate (1000 mg daily);
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cholecalciferol supplementation was replaced with calcifediol [125 mg (5000 IU) daily)]; at the
same time, caloric intake was raised up to 2500 kcal/d, with a high protein content. After
1 week serum albumin and calcium levels normalized. Serum PTH progressively decreased
with a parallel increase of serum phosphorus, and both reached normal levels after 1 month.
Serum 25(OH)D became detectable (7.8 ng/mL) after 4 days and reached a serum concen-
tration of 30.6 ng/mLafter 30 days. Serum levels ofBSAPprogressively declinedup to 70mg/mL
at discharge from our unit. The patient’s clinical conditions progressively improved, with a
substantial reduction of back pain and asthenia; furthermore, a rehabilitative program was
started, which led to a substantial recovery of autonomy.
During follow-up the calcifediol dose was progressively reduced up to the current dosage of
25 mg (1000 IU) daily, and calcitriol was definitively withdrawn after 2 months. Serum levels of
calcium,phosphorus, 25(OH)D,1,25-dihydroxyvitaminD,andPTHremained in thenormal range.
At the latest observation (January 2017) serum albumin was 3.6 g/dL, albumin-corrected
total calcium was 8.8 mg/dL, phosphate was 3.1 mg/dL, PTH was 46 pg/mL, 25(OH)D was
28 ng/mL, and BSAPwas 27 mg/mL (Fig. 2); however, some nutrition indexes remained below
the normal reference range.
Figure 1. 99mTc-oxidronate whole-body scan: numerous areas of pathological uptake at the
ribs, stern, hips, and cranium are present, consistent with a bone metabolic disorder.
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Dual x-ray absorptiometry revealed a marked improvement of BMD both at the total hip
(0.581 g/cm2, z score 22.8) and at the lumbar spine (0.695 g/cm2, z score 23.5), with an
increase of about 40% at both sites.
Serum concentration of vitamin D binding protein (DBP), measured using a turbidimetric
method [Dako, Denmark; adapted to RocheModularP (RocheDiagnostics)] in a serum sample
collected at this time, was 403 mg/L, a value slightly above the mean of the normal reference
population [3].
2. Discussion
Vitamin D deficiency is very common in obese patients and its origin is multifactorial. Se-
questration and dilution of vitamin D in the adipose tissue, reduced sun exposure, and the
influence of the inflammatory status related to obesity on vitamin D metabolism are ad-
vocated as themain determinants of the low vitaminD status among these patients [4, 5]. The
current guidelines of the US Endocrine Society recommend for obese subjects a vitamin D
intake twofold to threefold higher than for healthy, normal-weight adults [6].
Bariatric surgery for morbid obesity, particularly malabsorptive procedures such as bil-
iopancreatic diversion, is a well-known cause of severe vitamin D deficiency. Indeed, despite
the substantial weight loss following surgery and the use of vitamin D supplements in large
doses, data show that hypovitaminosis D persists and sometimes even worsens thereby [7].
TheAmericanAssociation of Clinical Endocrinologists, theObesity Society, and theAmerican
Society for Metabolic and Bariatric Surgery recommend the use of at least 3000 IU daily of
cholecalciferol in all patients following bariatric surgery, and the use of larger doses (up to
50,000 IU daily) in patients with severe malabsosorption states [8].
The patient described herein reflects the complexity of hypovitaminosis D management
after malabsorptive bariatric surgery. Indeed, despite the use of generous weekly doses of
cholecalciferol, she presented with undetectable serum levels of 25(OH)D and a clinical
picture characterized by hypocalcemia, muscle weakness, back pain, and osteomalacia,
complicated by atraumatic fractures.
Several mechanisms may contribute to the low serum 25(OH)D levels in our patient,
including malnutrition and its consequences, and malabsorption. Malnutrition may cause
impaired liver function, which may be associated with decreased levels of DBP and albumin
and, in severe cases, inability to hydroxylase vitamin D [9]. As a matter of fact, at initial
observation serum albumin, as well as other serum parameters, revealed an impaired liver
function, which improved during the follow-up. Unfortunately, we did not routinely measure
serum DBP. We were able to perform this assay only in a serum sample collected when the
general conditions of the patient were substantially improved, and at this time the con-
centration was normal. We cannot exclude that lower values could be present in an early
phase, but no stored serum samples were available for measuring DBP. This possibility could
be inferred on the basis of sequential measurement of albumin, which showed an increase of
~30% at the latest measurement compared with baseline.
It iswell known that chronicmalabsorption of liposoluble substances, such as cholecalciferol,
may occur following biliopancreatic diversion. Pharmacokinetic studies in healthy subjects
have shown that oral calcifediol supplementation is twofold to threefold more potent in rising
serum 25(OH)D concentration than cholecalciferol [10, 11]. Moreover, it is well known that
malabsorption of colecalciferol and, to a lower extent, of calcifediol occurs after gastrectomy, in
celiac diseases and other small bowel diseases [10, 12].Based on these considerations,we tested
the hypothesis that calcifediol, a more polar, water-soluble vitamin D metabolite that does not
require hepatic 25-hydroxylation, might be more effective than cholecalciferol in restoring a
normal vitamin D status. As a matter of fact, this treatment resulted in a rapid, progressive,
and stable normalization of serum levels of 25(OH)D and biochemical parameters of calcium
phosphatemetabolism,marked improvement of BMD, and resolution of the clinical symptoms.
The large increase of BMD over the 8-month period is likely related to the improvement of
vitamin D status and mineralization of unmineralized matrix.
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Figure 2. Serum levels of total albumin–corrected calcium, PTH, and 25(OH)D at baseline
and during follow-up, according to the treatment given to the patient. All parameters at the
last observation were in the normal range.
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It might be speculated that differences in therapeutic regimens, weekly for cholecalciferol
and daily for calcifediol, could account for the greater therapeutic efficacy of the latter. In this
regard, it is of note that no difference in the steady-state serum 25(OH)D levels were observed
when daily and weekly regimens of both vitamin D compounds were compared [11, 13].
No evidence-based guidelines for vitaminD supplementation aftermalabsorptive bariatric
surgery are available and no clinical trial on the use of calcifediol in this setting has been
performed, as yet.
In summary, the use of calcifediol rather than cholecalciferol, and the improvement of the
nutritional status, have contributed to the attainment of normal serum levels of 25(OH)D in
our patient. Based on our observation, we suggest that calcifediol should be considered as an
alternative to cholecalciferol in patients after malabsoptive bariatric surgery, a condition in
which lipid malabsorption and impaired liver function are present.
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